Patent Application
20230190916
A new strain of coronavirus first appeared in late 2019 in China before beginning its rapid spread across the globe [1]. The disease, named COVID-19, continues to cause severe pneumonia-like symptoms in many of those infected. In addition, it presents a much more severe disease course and fatality rate in the elderly. Coronaviruses, so named for their “crown-like” appearance, are a large family of viruses that spread from animals to humans and include diseases such as Middle East Respiratory Syndrome (MERS) and SARS in addition to COVID-19. While much remains unknown about the new coronavirus, it is known that the virus can spread via human-to-human transmission before any symptoms appear. The virus spike (S) protein binds to the human ACE2 protein for entry [1, 2]. This S protein, and specifically the conserved ACE-2 receptor binding domain (RBD), are potential targets for vaccine design. Antibodies directed to the S protein and the RBD have been shown to be neutralizing using in vitro assays for coronaviruses [3], suggesting that an effective vaccine can be produced to prevent SARS-CoV-2 infection.
Although current vaccines are effective in young adults, the elderly fail to respond well to many vaccines. Due to immunosenescence, which affects both innate and adaptive immunity, the elderly have decreased immune responses to vaccines [13, 14]. For example, 250,000 to 500,000 older patients aged over 65 years die annually because of influenza-related complications [15]. Since SARS-CoV-2 virus causes mortality disproportionately in the elderly, developing vaccines with better efficacy in aged population is an urgent public health need. Development of new adjuvants or combination of existing adjuvants that enhance the immunogenicity while maintaining an acceptable safety profile is one of the current strategies to improve the vaccine efficacy in elderly population.
There is a growing repertoire of substances being investigated as adjuvants. However, only a few adjuvants such as Aluminum salts (Alum), Monophosphoryl lipid A (MPL), MF59 (oil in water emulsion) and virosomes are approved by the FDA for human use [16]. Among the approved adjuvants, MF59 (biodegradable squalene in water emulsion) was developed specifically to address the low efficacy of influenza vaccine in elderly [17]. Fluad influenza vaccine (Novartis) containing MF59 as an adjuvant was shown to be 25% more effective compared to unadjuvanted trivalent inactivated influenza vaccine (TIV) in elderly patients [18, 19]. Although several phase III clinical trials involving aged patients using MPL or ASO3 (oil in water emulsion) were promising, the improvement was only incremental [15, 20, 21]. In addition, many TLR agonists have shown to be less effective in the elderly than in the young, primarily due to reduced signaling capacity and decreased TLR receptor expression in aged antigen presenting cells [22]. This is particularly relevant for TLR9 and CpG as an adjuvant for influenza viral vaccines [23]. Also, phagocytic and antigen cross-priming capacity in aging dendritic cells is impaired [24]. In addition, targeting of antigen to APC via GM-CSF receptor may enhance cross-priming. Adjuvants that have a tolerable safety profile and generate a Th1 immune response are of high importance. Alum, the first compound approved as an adjuvant, elicits a Th2 immune response rather than Th1, and is ineffective in inducing a strong cytotoxic-T lymphocyte (CTL) response [25, 26]. Several adjuvants (Alum, MPL, CpG, Poly I:C, and cholera toxin) have been investigated to enhance influenza VLP vaccines, but none have been commercially developed for use [27].
A number of studies documented the mechanism by which age dependent decline in immune response modulates functions of immune cells qualitatively and quantitatively. These studies also suggest some strategies to circumvent and improve the immune response in aged individuals [28, 29]. Aged mice produce lower levels of IgG in response to influenza infection, which could be the consequence of a compromised CD4 T helper response [29]. Cytokine combinations including TNF-α, IL-1β and IL-6 have been shown to improve CD4 T cell responses to provide help to B cells in aged mice. It was also shown that IL-6 dependent activation of dendritic cells from aged mice mitigates the age- associated decline in the initiation of immune response and survival of aged T cells [29]. Moreover, proinflammatory cytokines at the dendritic cell/T cell junction has been shown to play an important role in inducing a robust immune response [29].
It is well documented that cytokines increase the efficacy of vaccines by attracting and activating key immune cells. Two such cytokines being evaluated for their potential as adjuvants are Interleukin-12 (IL-12) and granulocyte macrophage colony-stimulating factor (GM-CSF). IL-12, a heterodimeric cytokine (p35 and p40 subunits), activates dendritic cells (DCs), T lymphocytes and natural killer (NK) cells to release IFN-y, TNF□ etc. [30-32]. IL-12 also sends a strong signal to T-helper cell precursors to differentiate towards a Th1 lineage, which also promotes development of a robust CTL response [33]. Pre-clinical and clinical trials performed to evaluate the potential of recombinant soluble IL-12 as an adjuvant in treating several cancers and viral hepatitis resulted in enhanced immune response [34-38], but also resulted in unfavorable side effects and systemic toxicity [39, 40]. However, membrane anchoring of IL-12 has been shown to prevent these unwanted side effects in a comprehensive toxicology studies in mice performed by Metaclipse even at 5X higher biologically active dose.
GM-CSF potentiates a strong immune response primarily through maturation and differentiation of dendritic cells [41-44]. Blood monocytes derived from young (<30 years) and old (> 65 years) people differentiate to DCs in response to GM-CSF and IL-4 and produce similar amounts of inflammatory cytokines like IL-12 and TNF-alpha when stimulated with whole inactivated influenza virus [45] suggesting that aged DCs are as effective as young when induced by cytokines like GM-CSF and IL-4. The FDA approved a prostate cancer vaccine, Provenge®, by Dendreon, uses a single antigen fused to GM-CSF and shown to effectively deliver antigen to the immune system [46, 47]. In several cancer vaccine development studies, co-administration of GM-CSF with either single or multiple peptide antigens showed cytotoxic T cell immune responses relative to vaccine alone [48-51]. Although many adjuvants including MF59 were effective in improving the influenza vaccine efficacy, they are known to induce several side effects because of reactogenicity and toxicity [29].
Provided herein are isolated recombinant polypeptides comprising a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide. In some embodiments, the recombinant polypeptide of claim 1, SARS-CoV-2 S1 protein binding domain polypeptide comprises a full-length S1 polypeptide. In some embodiments, the SARS-CoV-2 S1 protein binding domain polypeptide comprises SEQ ID NO:1 or a sequence at least 80% identical to SEQ ID NO:1. In some embodiments, the SARS-CoV-2 S1 protein binding domain polypeptide comprises SEQ ID NO: 6 or SEQ ID NO:7. In some aspects, the GM-CSF polypeptide comprises SEQ ID NO:2 or is at least 80% identical to SEQ ID NO:2.
Also provided herein are isolated recombinant polynucleotides comprising a SARS-CoV-2 S1 protein receptor binding domain (RBD) polynucleotide, a GM-CSF polynucleotide and a GPI-anchoring signal polynucleotide. In some embodiments, the SARS-CoV-2 S1 proteinreceptor binding domain polynucleotide and the GM-CSF polynucleotide are operably linked. In some embodiments, the SARS-CoV-2 S1 protein receptor binding domain polynucleotide comprises a full-length S1 polynucleotide. In some embodiments, the isolated recombinant polynucleotides comprising a SARS-CoV-2 S1 protein receptor binding domain (RBD) polynucleotide, a GM-CSF polynucleotide and a GPI-anchoring signal polynucleotide comprise SEQ ID NO:12. In some embodiments, the isolated recombinant polynucleotides comprising a SARS-CoV-2 S1 protein receptor binding domain (RBD) polynucleotide, a GM-CSF polynucleotide and a GPI-anchoring signal polynucleotide comprise SEQ ID NO:14.
Included herein are methods of detecting an antibody specific for a SARS-CoV-2 S1 protein receptor binding domain in a subject comprising, obtaining a blood sample from the subject, contacting the sample with a recombinant polypeptide comprising a SARS-CoV-2 S1 protein receptor binding domain polypeptide and a GM-CSF polypeptide, and detecting specific binding between the recombinant polypeptide and an antibody in the blood sample, wherein detection of specific binding indicates a presence of the antibody specific for a SARS-CoV-2 S1 protein receptor binding domain in the subject. In some aspects, the method of detection further comprises treating the subject for a SARS-CoV-2 infection. In some aspects, the subject is a human.
Also included herein are enveloped virus-like particles (VLPs) comprising a GPI-recombinant polypeptide anchored to the VLP, wherein the GPI-recombinant polypeptide comprises a SARS-CoV-2 S1 protein receptor binding domain polypeptide and a GM-CSF polypeptide (GPI-RBD-GM-CSF polypeptide). In some aspects, the VLP further comprises one or more GPI-immunostimulatory molecules anchored to the VLP. In some aspects, the one or more GPI-immunostimulatory molecules is a GPI-IL-12 molecule. In some aspects, the VLP is derived from an influenza virus, including, but not limited to, an influenza virus A/PR8. In some VLP embodiments, the SARS-CoV-2 S1 protein receptor binding domain polypeptide comprises SEQ ID NO:1 or comprises a sequence at least 80% identical to SEQ ID NO:1. In some VLP embodiments, the SARS-CoV2 S1 protein receptor binding domain polypeptide comprises SEQ ID NO:6 or SEQ ID NO:7, or comprises a sequence at least 80% identical to SEQ ID NO:6 or SEQ ID NO:7. In some VLP embodiments, the GM-CSF polypeptide comprises SEQ ID NO:2 or is at least 80% identical to SEQ ID NO:2.
Further included herein are methods for reducing a SARS-CoV-2 infection in a subject, comprising administering to the subject a therapeutically effective amount of an enveloped virus-like particle (VLP) described herein, wherein the infection in the subject is reduced as compared to a control. In some embodiments, the VLP further comprises one or more GPI-immunostimulatory molecules anchored to the VLP. In some embodiments, the GPI-immunostimulatory molecules is a GPI-IL-12 molecule.
Provided herein are compositions and methods for preventing or decreasing the severity of a SARS-CoV-2 infection in a subject and for detecting a SARS-CoV-2 infection in a subject. Included herein are recombinant polynucleotides comprising a SARS-CoV-2 S1 protein binding domain polynucleotide and a GM-CSF polynucleotide, recombinant polypeptides comprising a SARS-CoV-2 S1 protein binding domain polypeptide (RBD) and a GM-CSF polypeptide and virus-like particles that comprise the recombinant RBD-GM-CSF polypeptides.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. The following definitions are provided for the full understanding of terms used in this specification.
As used in the specification and claims, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “an agent” includes a plurality of agents, including mixtures thereof.
Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value” 10” is disclosed, then “about 10” is also disclosed.
“Administration” or “administering” to a subject includes any route of introducing or delivering to a subject an agent. Administration can be carried out by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like. “Concurrent administration”, “administration in combination”, “simultaneous administration” or “administered simultaneously” as used herein, means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time. “Systemic administration” refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject’s body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymphatic systems. By contrast, “local administration” refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount. For example, locally administered agents are easily detectable in the local vicinity of the point of administration, but are undetectable or detectable at negligible amounts in distal parts of the subject’s body. Administration includes self-administration and the administration by another.
As used herein, the term “comprising” is intended to mean that the compositions and methods include the recited elements, but not excluding others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
The expression “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. DNA for a presequence or secretory leader may be operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous.
The term “derived from” refers to a VLP that has been obtained from a virus. Methods of obtaining VLPs from viruses are well known to those of skill in the art and include the methods described herein and in U.S. Pat. No. 10,729,760.
The term “identity” “identical to” or “homology” shall be construed to mean the percentage of nucleotide bases or amino acid residues in the candidate sequence that are identical with the bases or residues of a corresponding sequence to which it is compared, after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent identity for the entire sequence, and not considering any conservative substitutions as part of the sequence identity. Neither N- nor C-terminal extensions nor insertions shall be construed as reducing identity or homology. A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) that has a certain percentage (for example, 80%, 85%, 90%, or 95%) of “sequence identity” to another sequence means that, when aligned over their full lengths, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art. In one embodiment, default parameters are used for alignment. In one embodiment a BLAST program is used with default parameters. In one embodiment, BLAST programs BLASTN and BLASTP are used with the following default parameters: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+SwissProtein+SPupdate+PIR.
As used herein, the terms “may,” “optionally,” and “may optionally” are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation “may include an excipient” is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
“Pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, e.g., the component may be incorporated into a pharmaceutical formulation of the invention and administered to a subject as described herein without causing significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained. When used in reference to administration to a human, the term generally implies the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
“Pharmaceutically acceptable carrier” (sometimes referred to as a “carrier”) means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic, and includes a carrier that is acceptable for veterinary and/or human pharmaceutical or therapeutic use. The terms “carrier” or “pharmaceutically acceptable carrier” can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil/water or water/oil emulsion) and/or various types of wetting agents. As used herein, the term “carrier” encompasses, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations and as described further herein.
The terms “polynucleotide” and “oligonucleotide” are used interchangeably, and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of this invention that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.
“Polypeptide” is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g. ester, ether, etc. As used herein the term “amino acid” refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
The terms “specific binding,” “specifically binds,” “selective binding,” and “selectively binds” mean that a polypeptide such as an antibody exhibits appreciable affinity for a particular binding partner polypeptide such as a SARS-CoV-2 S1 protein receptor binding domain polypeptide. Appreciable binding affinity includes binding with an affinity of at least 106 M-1, specifically at least 107 M-1, more specifically at least 108 M-1, yet more specifically at least 109 M-1, or even yet more specifically at least 1010 M-1. A binding affinity can also be indicated as a range of affinities, for example, 106 M-1 to 1010 M-1, specifically 107 M-1 to 1010 M-1, more specifically 108 M-1to 1010 M-1. Specific binding can be determined according to any art-recognized means for determining such binding. In some embodiments, specific binding is determined according to Scatchard analysis and/or competitive binding assays.
In some embodiments, “specific binding,” “specifically binds,” “selective binding,” and “selectively binds” when referring to a polypeptide (including antibodies) or receptor, refers to a binding reaction which is determinative of the presence of the protein or polypeptide or receptor in a heterogeneous population of proteins and other biologics. Thus, under designated conditions (e.g. immunoassay conditions in the case of an antibody), a specified ligand or antibody “specifically binds” to its particular “target” (e.g. an antibody specifically binds to an endothelial antigen) when it does not bind in a significant amount to other proteins present in the sample or to other proteins to which the ligand or antibody may come in contact in an organism. In some embodiments, a first molecule that “specifically binds” a second molecule has an affinity constant (Ka) greater than about 105 M-1 (e.g., 106 M-1, 107 M-1, 108 M-1, 109 M-1, 1010 M-1, 1011 M-1, and 1012 M-1 or more) with that second molecule.
The term “subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In some embodiments, the subject is a human.
“Therapeutically effective amount” or “therapeutically effective dose” of a composition (e.g. a composition comprising an agent) refers to an amount that is effective to achieve a desired therapeutic result. In some embodiments a desired therapeutic result is prevention of a SARS-CoV-2 viral infection or a reduction in the severity of a SARS-CoV-2 viral infection. In some embodiments, a desired therapeutic result is a reduction in an amount of detectable SARS-CoV-2 virus or antigen in a subject. Therapeutically effective amounts of a given agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, weight, and general condition of the subject. Thus, it is not always possible to specify a quantified “therapeutically effective amount.” However, an appropriate “therapeutically effective amount” in any subject case may be determined by one of ordinary skill in the art using routine experimentation. The term can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect. The precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the agent and/or agent formulation to be administered (e.g., the potency of the therapeutic agent, the concentration of agent in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art. It is understood that, unless specifically stated otherwise, a “therapeutically effective amount” of a therapeutic agent can also refer to an amount that is a prophylactically effective amount. In some instances, a desired biological or medical response is achieved following administration of multiple dosages of the composition to the subject over a period of days, weeks, or years.
“Treat,” “treating,” “treatment,” and grammatical variations thereof as used herein, include the administration of a composition with the intent or purpose of partially or completely, delaying, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing, mitigating, and/or reducing the intensity or frequency of one or more a diseases or conditions, a symptom of a disease or condition, or an underlying cause of a disease or condition. Treatments according to the invention may be applied, prophylactically, pallatively or remedially. Prophylactic treatments are administered to a subject prior to onset (e.g., before obvious signs of cancer), during early onset (e.g., upon initial signs and symptoms of cancer), or after an established development of cancer. Prophylactic administration can occur for day(s) to years prior to the manifestation of symptoms of a disease. In some embodiments, “treating” refers to prevention of a SARS-CoV-2 viral infection or a reduction in the severity of a SARS-CoV-2 viral infection in a subject as compared with prior to treatment of the subject or as compared with the incidence of such symptom in a general or study population. In some embodiments, “treating” refers to a reduction in an amount of detectable SARS-CoV-2 virus or antigen in a subject as compared with the incidence of such symptom in a general or study population.
As used herein the term “virus-like particle” is used interchangeably with “VLP” and refers to a structure that in at least one attribute resembles a virus, but which has not been demonstrated to be infectious. Virus-like particles in accordance with the invention lack a viral genome. In some embodiments, the virus-like particles comprise viral structural proteins. In some embodiments, the virus-like particles are enveloped, whereas in other embodiments, the virus-like particles are non-enveloped. Enveloped VLPs comprise a lipid bilayer. In some embodiments, the virus-like particles are derived from an influenza virus. The influenza virus VLPs can be derived from any of influenza virus A, influenza virus B, influenza virus C and influenza virus D. In some embodiments, the influenza virus VLPs are derived from influenza virus A/PR8 (H1N1).
As used herein, the term “anchored to the VLP” refers to the insertion of an exogenous polypeptide such as GM-CSF, SARS CoV-2 S1 subunit receptor binding domain (RBD) and/or IL-12 at the exterior of the VLP surface. The term “anchored to the VLP” does not refer to endogenous polypeptides naturally expressed at a cell’s surface before viral budding from the cell. In some embodiments, the exogenous polypeptide is anchored to the lipid bilayer of the VLP via a glycosyl-phosphatidyl-inositol (GPI) molecule. In some embodiments, the GPI-anchor comprises a glycosylated moiety attached to phosphatidylinositol containing two fatty acids. In some embodiments, a GPI molecule is composed of a phosphatidylinositol group linked through a carbohydrate-containing linker (such as glucosamine and mannose glycosidically bound to the inositol residue) and an ethanolamine phosphate (EtNP), wherein the EtNP is attached to the C-terminal amino acid of the polypeptide. The two fatty acids within the phosphatidyl-inositol group anchor the polypeptide to the VLP membrane.
As explained above, the present invention includes compositions and methods for preventing or decreasing the severity of a SARS-CoV-2 infection in a subject and for detecting a SARS-CoV-2 infection in a subject. A SARS-CoV-2 infection is commonly referred to as a “coronavirus infection.” Also included herein are recombinant polynucleotides comprising a SARS-CoV-2 S1 protein receptor binding domain (RBD) polynucleotide and a GM-CSF polynucleotide, recombinant polypeptides comprising a SARS-CoV-2 S1 protein receptor binding domain polypeptide (RBD) and a GM-CSF polypeptide, and virus-like particles (VLPs) that comprise the recombinant RBD-GM-CSF polypeptides in a GPI-anchor form. In some embodiments, the VLPs further comprise a GPI-anchored form of one or more immunostimulatory molecules (referred to herein as a GPI-immunostimulatory molecule). As used herein “immunostimulatory molecule” refers to any molecule that, when attached to a VLP, can stimulate or co-stimulate an immune response to a SARS-CoV-2 virus. In some embodiments, the one or more immunostimulatory molecules are cytokines. In some embodiments, the cytokine is an IL-12.
GPI-anchored molecules are incorporated into virus-like particles (VLPs) by a ‘protein transfer’ technique. In this approach, polypeptides are converted to GPI-anchored forms by attaching the DNA sequence corresponding to a cytokine to the DNA sequence corresponding to the GPI-anchor signal sequence from naturally occurring GPI-anchored CD59. In some embodiments, the GPI-anchor comprises a glycosylated moiety attached to phosphatidylinositol containing two fatty acids. The GPI-anchor permits incorporation of GPI-anchored proteins into the lipid bilayer of influenza VLPs [52]. By introducing membrane incorporated GPI-cytokines into VLPs, multiple viral-specific antigens can be presented to the immune system to mount a robust immune response. In addition, administration of VLP vaccines containing membrane-anchored cytokines will localize the cytokines to the area of injection, thereby reducing the toxic effects associated with soluble cytokines.
According to the present invention, the SARS-CoV-2 S1 protein receptor binding domain (RBD) refers to the region of the SARS CoV-2 spike protein that specifically binds to a receptor ACE2 on a host cell. In some embodiments, the RBD polypeptide comprises amino acids 319 through 541 of the spike protein. In some embodiments, the RBD polypeptide comprises SEQ ID NO:1. It should be understood, however, that as used herein, a SARS-CoV-2 S1 protein receptor binding domain polynucleotide or polypeptide refers to any polynucleotide or polypeptide that comprises the region of the SARS CoV-2 spike protein that specifically binds to a receptor ACE2 on a host cell. Accordingly, a SARS-CoV-2 S1 protein receptor binding domain polynucleotide or polypeptide includes a full-length S1 polynucleotide or polypeptide, and any fragment thereof that includes the region of the SARS CoV-2 spike protein that specifically binds to a receptor ACE2 on a host cell. In some embodiments, the SARS-CoV-2 S1 protein receptor binding domain polypeptide comprises SEQ ID NO:6 or SEQ ID NO:7.
The GM-CSF polynucleotides and polypeptides can be human or of another species. In some embodiments, the GM-CSF polynucleotides and polypeptides are murine. In other embodiments, the GM-CSF polynucleotides and polypeptides are human. In some embodiments, the GM-CSF polynucleotide or polypeptide is that found in one or more publicly available databases as follows: HGNC: 2434, Entrez Gene: 1437, Ensembl: ENSG00000164400, OMIM: 138960, and UniProtKB: P04141. In some embodiments, the IL-12 comprises a polypeptide sequence having about 70% or greater, about 75% or greater, about 80% or greater, about 85% or greater, about 90% or greater, about 95% or greater, or about 98% or greater homology or identity with SEQ ID NO:2.
The recombinant polypeptides comprising a RBD polypeptide and a GM-CSF polypeptide can be any combination of the above referenced polypeptides. In some embodiments, the GM-CSF polypeptide is attached to the GPI-anchor. In other embodiments the RBD polypeptide is attached to the GPI-anchor.
In some embodiments, IL-12 comprises IL-12a and IL-12b. In some embodiments, the IL-12 comprises the sequence of SEQ ID NO:3, or a fragment thereof. In some embodiments, the IL-12 polynucleotide or polypeptide is that found in one or more publicly available databases as follows: HGNC: 5969 Entrez Gene: 3592 Ensembl: ENSG00000168811 OMIM: 161560 UniProtKB: P29459. In some embodiments, the IL-12 comprises a polypeptide sequence having about 70% or greater, about 75% or greater, about 80% or greater, about 85% or greater, about 90% or greater, about 95% or greater, or about 98% or greater homology or identity with SEQ ID NO:3.
In some embodiments, the IL-12 polynucleotide or polypeptide is that found in one or more publicly available databases as follows: HGNC: 5970 Entrez Gene: 3593 Ensembl: ENSG00000113302 OMIM: 161561 UniProtKB: P29460. In some embodiments, the IL-12 comprises a polypeptide sequence having about 70% or greater, about 75% or greater, about 80% or greater, about 85% or greater, about 90% or greater, about 95% or greater, or about 98% or greater homology or identity with SEQ ID NO:4.
As used herein “GPI-recombinant polypeptide” refers to a recombinant polypeptide having a GPI anchor. “GPI-immunostimulatory molecule” refers to an immunostimulatory molecule having a GPI anchor. GPI-anchored polypeptides can be created through the addition of a GPI anchor signal sequence to the polypeptide. A GPI anchor signal sequence is a sequence that directs GPI anchor addition to the polypeptide. One example of a GPI anchor signal sequence that may be added to a polypeptide is SEQ ID NO:5, a CD59 GPI anchor signal sequence. Accordingly, in some embodiments, the immunostimulatory agent, antigen, or other molecules attached to the lipid membrane include a GPI anchor signal sequence.
A number of proteins commonly expressed by cells are attached to the cell membrane via a GPI-anchor. These proteins are post-translationally modified at their carboxy terminus to express this glycosylated moiety which is synthesized in the endoplasmic reticulum. These naturally expressing GPI-anchored molecules are widely distributed in mammalian cells and serve a host of different cellular functions, such as cell adhesion, enzymatic activity, and complement cascade regulation. Naturally occurring GPI- anchored proteins lack a transmembrane and cytoplasmic domain that otherwise anchor membrane proteins. The GPI-anchor consists of a glycosylated moiety attached to phosphatidylinositol containing two fatty acids. The phosphatidylinositol portion, as well as an ethanolamine which is attached to the C-terminal of the extracellular domain of the membrane proteins, anchor the molecule to the cell membrane lipid bilayer.
In order to exploit this natural linkage using recombinant DNA techniques, the transmembrane and cytoplasmic domains of a transmembrane surface protein need only be replaced by the signal sequence for GPI-anchor attachment that is found at the hydrophobic C-terminus of GPI-anchored protein precursors. This method may be used to generate GPI- anchored proteins is not limited to membrane proteins; attaching a GPI-anchor signal sequence to a secretory protein also converts the secretory protein to a GPI-anchored form. The method of incorporating the GPI-anchored proteins onto isolated cell surfaces or TMVs is referred to here as protein transfer.
GPI-anchored molecules can be incorporated onto lipid membranes spontaneously. GPI-anchored proteins can be purified from one cell type and incorporated onto cell membranes of a different cell type. GPI-anchored proteins can be used to customize the lipid membranes disclosed herein. Multiple GPI-anchored molecules can be simultaneously incorporated onto the same cell membrane. The amount of protein attached to the VLP can be controlled by simply varying the concentration of the GPI-anchored molecules to be incorporated onto membranes. A significant advantage of this technology is the reduction of time in preparing vaccines from months to hours. These features make the protein transfer approach a more viable choice for the development of cancer vaccines for clinical settings. The molecules incorporated by means of protein transfer retain their functions associated with the extracellular domain of the native protein.
In some embodiments, the polynucleotide encoding a SARS-CoV-2 S1 protein binding domain polypeptide comprises SEQ ID NO:8 or a polynucleotide sequence having about 70% or greater, about 75% or greater, about 80% or greater, about 85% or greater, about 90% or greater, about 95% or greater, or about 98% or greater homology or identity with SEQ ID NO:8.
In some embodiments, the recombinant polynucleotide encoding a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide comprises SEQ ID NO:12 or SEQ ID NO:14. In some embodiments, the recombinant polynucleotide encoding a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide comprises has about 70% or greater, about 75% or greater, about 80% or greater, about 85% or greater, about 90% or greater, about 95% or greater, or about 98% or greater homology or identity with SEQ ID NO: 12 or SEQ ID NO:14. In some embodiments, the recombinant polynucleotide encoding a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide comprises a GPI-anchoring signal polynucleotide, a S1 protein binding domain polynucleotide and a human GM-CSF polynucleotide of SEQ ID NO: 12. SEQ ID NO: 14 is a fusion polynucleotide consisting of the human GM-CSF and SARS CoV-2 S protein RBD encoding a glycoprotein with a Glycosylphosphatidylinositol anchor. Its molecular weight is approximately 60 kD. The deduced encoded amino acid sequence is identical to the sequence for mouse GM-CSF and SARS-CoV-2 S protein RBD (except for N501Y, E484K, and K417N mutations described in the South Africa mutant SARS-CoV-2 virus) attached to the GPI anchor from human CD59.
In some embodiments, the recombinant polynucleotide encoding a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide comprises SEQ ID NO:11 or SEQ ID NO:13. In some embodiments, the recombinant polynucleotide encoding a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide comprises has about 70% or greater, about 75% or greater, about 80% or greater, about 85% or greater, about 90% or greater, about 95% or greater, or about 98% or greater homology or identity with SEQ ID NO:11 or SEQ ID NO:13. SEQ ID NO:11 comprises a GPI-anchoring signal polynucleotide, a S1 protein binding domain polynucleotide and a mouse GM-CSF polynucleotide. SEQ ID NO:13 is a fusion polynucleotide consisting of the mouse GM-CSF and SARS CoV-2 S protein RBD encoding a glycoprotein with a Glycosylphosphatidylinositol anchor. Its molecular weight is approximately 60 kD. The deduced encoded amino acid sequence is identical to the sequence for mouse GM-CSF and SARS-CoV-2 S protein RBD (except for N501Y, E484K, and K417N mutations described in the South Africa mutant SARS-CoV-2 virus) as well as the addition of 10 amino acids to the C-terminus) attached to the GPI anchor from human CD59.
Disclosed herein is a method for detecting an antibody specific for a SARS-CoV-2 S1 protein binding domain in a subject comprising, obtaining a blood sample from the subject, contacting the sample with a recombinant polypeptide comprising a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide, and detecting specific binding between the recombinant polypeptide and an antibody in the blood sample, wherein detection of specific binding indicates a presence of the SARS-CoV-2 S1 protein binding domain in the subject. In some embodiments, the detecting method further comprises treating the subject for a SARS-CoV-2 infection.
One method for treating a SARS-CoV-2 infection in a subject comprises administering to the subject a therapeutically effective amount of an enveloped virus-like particle (VLP) comprising a GPI-recombinant polypeptide comprising a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide (GPI-RBD-GM-CSF) anchored to the VLP. In some embodiments, the enveloped VLP further comprises a GPI-IL-12 molecule anchored to the VLP.
For all of the detection and treatment methods, the VLP, the GPI-RBD-GM-CSF and the GPI-IL-12 can be any as described herein.
The subject can be any mammalian subject, for example a human, dog, cow, horse, mouse, rabbit, etc. In some embodiments, the subject is a primate, particularly a human. The subject can be a male or female of any age, race, creed, ethnicity, socio-economic status, or other general classifiers.
In the treatment methods, the dosage forms of the compositions disclosed herein can be adapted for administration by any appropriate route. Appropriate routes include, but are not limited to, oral (including buccal or sublingual), rectal, epidural, intracranial, intraocular, inhaled, intranasal, topical (including buccal, sublingual, or transdermal), vaginal, intraurethral, parenteral, intracranial, subcutaneous, intramuscular, intravenous, intraperitoneal, intradermal, intraosseous, intracardiac, intraarticular, intracavenous, intrathecal, intravitreal, intracerebral, gingival, subgingival, intracerebroventricular, and intradermal. Such formulations may be prepared by any method known in the art.
The disclosed treatment methods can be performed any time prior to and/or after the onset of a disease (e.g., a SARS-CoV-2 infection) or administration of a vaccine. In some aspects, the disclosed methods can be employed 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 years;12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 months; 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 days; 60, 48, 36, 30, 24, 18, 15, 12, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours prior to the onset of a disease (e.g., SARS-CoV-2 infection) or administration of a vaccine; or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 105, 120 minutes; 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 24, 30, 36, 48, 60 hours; 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 45, 60, 90 or more days; 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months; 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 years after the onset of a disease (e.g., SARS-CoV-2 infection) or administration of a vaccine.
Dosing frequency for the compositions disclosed herein, includes, but is not limited to, at least once every 12 months, once every 11 months, once every 10 months, once every 9 months, once every 8 months, once every 7 months, once every 6 months, once every 5 months, once every 4 months, once every 3 months, once every two months, once every month; or at least once every three weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or daily. In some embodiment, the interval between each administration is less than about 4 months, less than about 3 months, less than about 2 months, less than about a month, less than about 3 weeks, less than about 2 weeks, or less than less than about a week, such as less than about any of 6, 5, 4, 3, 2, or 1 day. In some embodiment, the dosing frequency for the T cells disclosed herein includes, but is not limited to, at least once a day, twice a day, or three times a day. In some embodiment, the interval between each administration is less than about 48 hours, 36 hours, 24 hours, 22 hours, 20 hours, 18 hours, 16 hours, 14 hours, 12 hours, 10 hours, 9 hours, 8 hours, or 7 hours. In some embodiment, the interval between each administration is less than about 24 hours, 22 hours, 20 hours, 18 hours, 16 hours, 14 hours, 12 hours, 10 hours, 9 hours, 8 hours, 7 hours, or 6 hours. In some embodiment, the interval between each administration is constant. For example, the administration can be carried out daily, every two days, every three days, every four days, every five days, or weekly. Administration can also be continuous and adjusted to maintaining a level of the compound within any desired and specified range.
All patents, patent applications, and publications referenced herein are incorporated by reference in their entirety for all purposes.
To further illustrate the principles of the present disclosure, the following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compositions, articles, and methods claimed herein are made and evaluated. They are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their disclosure. These examples are not intended to exclude equivalents and variations of the present invention which are apparent to one skilled in the art. Unless indicated otherwise, temperature is °C or is at ambient temperature, and pressure is at or near atmospheric. There are numerous variations and combinations of process conditions that can be used to optimize product quality and performance.
In brief, these studies strongly suggest that: (1) GPI- cytokine-modified VLPs enhance virus-specific IgG responses in young and aged mice, (2) GPI-cytokine modified VLPs, but not VLPs alone, confer protection against heterologous influenza challenge, (3) cross-protective efficacy is granted to aged mice when immunized with GPI-cytokine modified VLPs, and (4) Aged mice demonstrate enhanced IgG responses to a heterologous virus after immunization with GPI-cytokine modified VLPs in comparison to VLP alone.
As reported previously, the incorporation of GPI-GM-CSF is dependent on the incubation time and concentration of GPI-GM-CSF [52]. In some embodiments, the GPI-anchored polypeptide is incubated for one hour at 37° C. The incorporation was dependent on the presence of the GPI-anchor and incorporated GPI-GM-CSF was stable at least for 4 weeks [52]. VLP-Incorporated GPI-GM-CSF is also functional in activating the proliferation of dendritic cells from BALB/c mice for up to 4 weeks [52]. In addition, dual incorporation of GPI-GM-CSF and GPI-IL-12 induces maturation of both young and aged bone marrow derived dendritic cells as measured by increased expression of CD80, CD86, and MHC Class II (data not shown). These findings indicate that it is possible to produce VLPs from human viruses and modify with functionally active GPI-GM-CSF and GPI-IL-12 by protein transfer and that dendritic cells from aged mice proliferate and mature in a comparable manner to young dendritic cells to GPI-cytokine modified VLPs. In addition, we did not expect any significant differences in proliferative capacity or maturation capacity between young and aged mice [45].
Influenza VLPs transferred with GPI-GM-CSF and GPI-IL-12 enhance homologous antibody responses in both young and aged mice (
GPI-cytokine modified VLP vaccines provide enhanced cross protection against an antigenically diverse influenza virus in young adult mice (
Aged mice (18 months old) were immunized as described with PBS, HA-VLP alone, or HA-VLP-Cyt. As depicted in
Addition of GPI-GM-CSF and GPI-IL-12 to influenza VLPs significantly enhances amnestic antibody production in aged mice. Serum antibody production against a heterologous influenza (WSN) virus was enhanced after vaccination with GPI-cytokine modified VLP in comparison to VLP alone. Total IgG, IgG1, and IgG2A responses against heterologous Influenza WSN were increased in aged mice (
A fusion protein gene was constructed by joining the RBD domain sequence with GM-CSF and a GPI-anchor signal sequence from CD59 (
Fusion protein was purified by Immunoaffinity chromatography using rat anti-mouse GM-CSF antibody (Clone MP1-22E9, Bio X cell) coupled to NHS-Sepharose beads. The fusion protein runs at 60-65 kDa on SDS-PAGE (
In order to determine whether GPI-RBD-GM-CSF protein can be recognized by the antibodies generated against SARS-CoV2 virus in patients, an ELISA was performed to detect the binding of antibodies in the convalescent plasma to plate bound fusion protein (
PR8 influenza VLPs were produced as previously described [56] and as described below. Toxicology-grade Influenza VLPs (A/PR8) will be provided by Medigen, Inc. (Frederick, Maryland).
VLP Production: Virus and cells. Spodoptera frugiperda Sf9 cells were maintained in suspension in serum-free SF900II medium (GIBCO-BRL) at 27° C. in spinner flasks at a speed of 70 to 80 rpm. CV-1 and Madin-Darby canine kidney (MDCK) cells were grown and maintained in Dulbecco’s modified Eagle’s medium (DMEM). Mouse-adapted influenza A/PR8/34 and A/WSN/33 viruses were prepared as lung homogenates from intranasally infected mice. Preparation of influenza VLPs. A cDNA for influenza virus M1 (A/PR8) was obtained. The M1 gene was PCR amplified with primers containing flanking restriction enzyme sites for cloning into the pSP72 plasmid expression vector under the T7 promoter (forward primer, 5′ TCC CCCGGG CCACC ATG AGC CTT CTG ACC GAG GTC 3′ (SEQ ID NO:9); reverse primer, 5′ TTA CT TCTAGA TTA CTT GAA CCG TTG CAT CTG 3′ (SEQ ID NO:10); SmaI and XbaI sites are underlined). The pSP72 clone containing the M1 gene was confirmed by DNA sequencing, and the expression of the M1 protein was confirmed by Western blot analysis of CV-1 cells transfected with pSP72 containing the M1 gene following infection with a recombinant vaccinia virus expressing T7 polymerase. The M1 gene was subcloned into the SmaI and XbaI site in the baculovirus transfer vector pc/pS 1 containing a hybrid capsid-polyhedrin promoter. To produce a recombinant baculovirus (rBV) expressing M1, Sf9 insect cells were cotransfected with Baculogold DNA (BD/PharMingen) and the pc/pS1-M1 transfer vector by following the manufacturer’s instructions. The supernatant was harvested 5 days after transfection, and recombinant plaques expressing M1 were selected by plaque assay and expanded.
For Western blot analysis to determine the expression of M1 and HA, transfected or infected cells were dissolved in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) sample buffer (50 mM Tris, 3% β-mercaptoethanol, 2% SDS, 10% glycerol), separated by SDS-PAGE, and then probed with mouse anti-M1 antibody (1:4,000; Serotec) and sera from PR8 virus-infected mice (1:1,000). The virus titer was determined with a Fast Plax titration kit according to the manufacturer’s instructions (Novagen, Madison, WI).
To produce VLPs containing influenza virus M1 and HA, Sf9 cells were coinfected with rBVs expressing HA and M1 at multiplicities of infection of 4 and 2, respectively. Culture supernatants were harvested at 3 days post-infection, cleared by low-speed centrifugation (2,000 × g for 20 min at 4° C.) to remove cells, and VLPs in the supernatants were pelleted by ultracentrifugation (100,000 × g for 60 min). The sedimented particles were resuspended in phosphate-buffered saline (PBS) at 4° C. overnight and further purified through a 20%-30%-60% discontinuous sucrose gradient at 100,000 × g for 1 h at 4° C. The VLP bands were collected and analyzed by using Western blots probed with anti-M1 antibody and mouse anti-PR8 sera for detecting M1 and HA, respectively. The level of residual rBV in the purified VLPs was determined by plaque assay, and equivalent titers of HA-expressing rBVs were estimated to contribute less than 5% of HA in VLPs as determined by Western blotting. The functionality of HA incorporated into VLPs was assessed by hemagglutination activity using chicken red blood cells as described previously. Alternatively, VLPs can be purified using tangential flow diafiltration followed by ion exchange chromatography (Capto Q column).
In addition, release testing assays for VLP vaccine will be established. These assays will include size of VLP as measured by a Malvern Zetasizer, overall protein concentration by micro BCA assay, incorporation efficiency of GPI-anchored cytokines and fusion protein into VLPs as measured by western blot and flow cytometry, and in vitro functional assays for biological activity of the RBD domain and GM-CSF. Binding of the RBD domain to human ACE2 receptor will be used to demonstrate functional activity. Reporter cells for human GM-CSF (Tf1, ATCC) and mouse/human IL-12 (HEK-Blue IL-12), Invivogen) are commercially available.
GPI-RBD-GM-CSF fusion protein retains structural and functional activity. To determine whether the fusion protein expressed in the CHO-S cells retain the ability to bind to the anti-RBD antibodies and retain the function of fusion partner GM-CSF, we have performed flow cytometry (
VLP vaccine induces durable antibody response and neutralizes the virus. BALB/c (2-3 months old) mice were immunized with GPI-GM-CSF-RBD fusion protein (0.1, 1.0, 2.0 and 5.0 µg), VLPs (1.0, 2.0, 5.0 and 10 µg) incorporated with the fusion protein and GPI-IL-12 and control VLP without cytokines and commercially available RBD (Ray Biotech) or PBS. Booster dose was given 2 weeks after the first dose. The route of administration was either subcutaneous (s.c.) or intramuscular (i.m.).
Blood was collected every 2 - 4 weeks for antibody titer, ACE2 binding inhibition, and virus microneutralization. VLP vaccine induces robust antibody response both i.m. (
Publications cited herein are hereby specifically incorporated by reference in their entireties and at least for the material for which they are cited.
This application is a national phase entry under 35 U.S.C. §371 of International Application No. PCT/US2021/032541, filed May 14, 2021, which claims the benefit of U.S. Provisional Application No. 63/024,615, filed May 14, 2020, which are expressly incorporated herein by reference in their entireties.
This invention was made with government support under CA202763 and CA221559 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2021/032541 | 5/14/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63024615 | May 2020 | US |
